Trials / Recruiting
RecruitingNCT06773195
A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
A Phase 1/2 Study of Combined JAK/ERK Inhibition in Patients With Myelofibrosis
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 37 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The researchers are doing this study to find out whether the combination of ruxolitinib and ulixertinib is a safe and effective treatment for people with myelofibrosis. The researchers will test different doses of ulixertinib to find the highest dose that causes few or mild side effects in participants when given in combination with ruxolitinib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ulixertinib | There are 3 planned dose levels of ulixertinib(450 mg BID, 300 mg BID, or 150 mg BID) |
| DRUG | Ruxolitinib | Ruxolitinib for 28 day cycles. |
Timeline
- Start date
- 2025-01-07
- Primary completion
- 2028-01-01
- Completion
- 2028-01-01
- First posted
- 2025-01-14
- Last updated
- 2026-04-03
Locations
9 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06773195. Inclusion in this directory is not an endorsement.